If you have been reading about GABA-A modulation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-06. Numbers and descriptions here follow the published literature rather than marketing material.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
| Property | Value | Notes |
|---|---|---|
| Common route | Intranasal | Also injected in some animal work |
| Solubility class | Freely soluble in water | Solid form is hygroscopic |
| Typical storage | About -20 degrees Celsius | Keep desiccated and dark |
| Purity method | Reverse-phase HPLC | Reported as area percent |
| Confirmatory method | Mass spectrometry | Verifies expected molecular mass |
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Fold Type I — aspartate aminotransferase family Fold Type II — tryptophan synthase family Fold Type III — alanine racemase family (TIM-barrel) Fold Type IV — D-amino acid aminotransferase family Fold Type V — glycogen phosphorylase family
== Factors affecting elasticity == In a given isotropic solid, with known theoretical elasticity for the bulk material in terms of Young's modulus, the effective elasticity will be governed by porosity. Generally a more porous material will exhibit lower stiffness. More specifically, the fraction of pores, their distribution at different sizes and the nature of the fluid with which they are filled give rise to different elastic behaviours in solids. For isotropic materials containing cracks, the presence of fractures affects the Young and the shear moduli perpendicular to the planes of the cracks, which decrease (Young's modulus faster than the shear modulus) as the fracture density increases, indicating that the presence of cracks makes bodies brittler. Microscopically, the stress–strain relationship of materials is in general governed by the Helmholtz free energy, a thermodynamic quantity. Molecules settle in the configuration which minimizes the free energy, subject to constraints derived from their structure, and, depending on whether the energy or the entropy term dominates the free energy, materials can broadly be classified as energy-elastic and entropy-elastic. As such, microscopic factors affecting the free energy, such as the equilibrium distance between molecules, can affect the elasticity of materials: for instance, in inorganic materials, as the equilibrium distance between molecules at 0 K increases, the bulk modulus decreases. The effect of temperature on elasticity is difficult to isolate, because there are numerous factors affecting it.
Genes for human growth hormone, known as growth hormone 1 (somatotropin; pituitary growth hormone) and growth hormone 2 (placental growth hormone; growth hormone variant), are localized in the q22-24 region of chromosome 17 and are closely related to human chorionic somatomammotropin (also known as placental lactogen) genes. GH, human chorionic somatomammotropin, and prolactin belong to a group of homologous hormones with growth-promoting and lactogenic activity.
Anti-drug efforts were seen as making progress by 37%, losing ground by 29%, and staying the same by 30%; 56% believed that the US and Mexico are both to blame for drug violence in Mexico. As of 2024, the DEA considers the Sinaloa and Jalisco cartels, tied to materials and services from China, as the major source of synthetic drugs like fentanyl and methamphetamine, posing the biggest threat to the US. According to federal court documents in Manhattan, Gerardo Merida Sanchez—a former public security official in the Mexican state of Sinaloa—is accused of teaming up with leaders of the Sinaloa cartel to sneak large amounts of drugs into the United States. The indictment says he took more than $100,000 a month in bribes from Los Chapitos to protect the cartel's smuggling routes into the U.S. He was arrested in Arizona on May 11 and then transferred to New York. This case shows how drug production and trafficking networks in Mexico play a role in supplying a large share of the illegal drugs that end up being used in the United States.
== Applications == Targeted analysis allows the thorough analysis of all ions, at all abundance range above the noise level, at any time window in the experiment. In contrast, non-targeted analysis would, typically, only allow detection of the most abundant 50-100 ions over the entire experiment time. Such limitation of non-targeted analysis makes it less suitable for analyzing highly complex, highly dynamic sample such as human blood serum. However, the methods of utilizing targeted mass spectrometry are still at a primitive stage, in the sense that the inclusion list used in the targeted analysis is typically manually typed-in by scientists. In addition to that, only one inclusion list is allowed for the entire experiment. Such manual process is both labor-intensive and error-prone. This is largely due to the lack of software to control the mass spectrometer.
Sources: en.wikipedia.org
Pinoline, also known as 6-methoxytryptoline or as 6-methoxy-1,2,3,4-tetrahydro-β-carboline (6-MeO-THβC), is a β-carboline long-claimed to be produced in the pineal gland during the metabolism of melatonin, however its pineal occurrence remains controversial. Its more common name is a contraction of "pineal β-carboline". The biological activity of this molecule is of interest as a potential free radical scavenger, also known as an antioxidant, and as a monoamine oxidase A inhibitor.
In collaboration with the team at the Lawrence Livermore National Laboratory (LLNL) in Livermore, California, United States, they made an attempt on element 114 (which was predicted to be a magic number, closing a proton shell, and more stable than element 113). In 1998, the JINR–LLNL collaboration started their attempt on element 114, bombarding a target of plutonium-244 with ions of calcium-48:
== Origin == There are conflicting stories about the dessert's origin. Some claim that it was first served during the 1893 Chicago World's Fair, where the ice cream sundae was also invented. Though in 1894, a Philadelphia company was given credit for its invention describing: "A small, solid [cake] of the ice cream is enveloped in a thin sheet of pie crust and then dipped into boiling lard or butter to cook the outside to a crisp. Served immediately, the ice cream is found to be as solidly frozen as it was first prepared." It may be derived in part from Baked Alaska, originating earlier in the 19th century, which puts ice cream under a quickly broiled meringue.
== Taxonomy == The Wagler's pit viper has undergone much taxonomic reclassification over the years and was previously placed in the genus Trimeresurus. However, its distinctly different morphology and venom characteristics set it apart, so that eventually a new genus was erected in which it was placed together with Hutton's viper, Tropidolaemus huttoni.
Sources: en.wikipedia.org
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.
Reported human trials are few, brief and originate mainly from one country. They describe effects on anxiety-related measures, but sample sizes are small and reporting is limited. The results are widely regarded as preliminary rather than confirmed.
Reverse-phase liquid chromatography is used to assess purity and separation of related impurities. Mass spectrometry confirms that the observed molecular mass matches the expected peptide. A certificate of analysis from the supplier is the usual document of record.
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.